Zanosar 1 g ノルウェー - ノルウェー語 - Statens legemiddelverk

zanosar 1 g

esteve pharmaceuticals s.a.s. - streptozocin - pulver til konsentrat til infusjonsvæske, oppløsning - 1 g

Mayzent 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

mayzent

novartis europharm limited  - siponimod fumaric syre - multippel sklerose, relapsing-remitting - selektive immunosuppressiva - mayzent er indisert for behandling av voksne pasienter med sekundær progressiv multippel sklerose (spms) med aktiv sykdom dokumentert ved tilbakefall eller bildebehandling funksjoner av inflammatorisk aktivitet.

Sapropterin Dipharma 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - andre alimentary tract and metabolism products, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Vyepti 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

vyepti

h. lundbeck a/s - eptinezumab - migrene lidelser - analgetika - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Pepaxti 欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Sitagliptin/Metformin Glenmark 50 mg / 850 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

sitagliptin/metformin glenmark 50 mg / 850 mg

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg

Sitagliptin/Metformin Glenmark 50 mg / 1000 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

sitagliptin/metformin glenmark 50 mg / 1000 mg

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Sitagliptin/Metformin Medical Valley 50 mg / 850 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

sitagliptin/metformin medical valley 50 mg / 850 mg

medical valley invest ab - sitagliptinhydroklorid / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg

Sitagliptin/Metformin Medical Valley 50 mg / 1000 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

sitagliptin/metformin medical valley 50 mg / 1000 mg

medical valley invest ab - sitagliptinhydroklorid / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Sapropterin Teva 100 mg ノルウェー - ノルウェー語 - Statens legemiddelverk

sapropterin teva 100 mg

teva gmbh - sapropterindihydroklorid - oppløselig tablett - 100 mg